Description
BSE revokes the suspension of trading in equity shares of Vivimed Labs Ltd. (Scrip Code: 532660), allowing normal trading to resume.
Summary
BSE has issued a circular revoking the suspension of trading in equity shares of Vivimed Labs Ltd. (Scrip Code: 532660). This action lifts the previously imposed trading restrictions, permitting normal trading operations to resume for the company’s shares on the exchange.
Key Points
- Trading suspension for Vivimed Labs Ltd. equity shares has been revoked
- Scrip Code: 532660
- Normal trading activities can now resume
- The revocation indicates the company has likely fulfilled compliance requirements or resolved issues that led to the original suspension
Regulatory Changes
The suspension status has been changed from suspended to active, restoring normal trading capabilities for Vivimed Labs Ltd. equity shares.
Compliance Requirements
No specific compliance requirements are mentioned for market participants. The company has presumably met the necessary conditions for revocation of the suspension.
Important Dates
- Circular Date: December 10, 2025
- Effective Date: As per the circular issuance
Impact Assessment
This revocation has a positive impact on:
- Investors: Shareholders can now trade shares freely without restrictions
- Company: Vivimed Labs Ltd. regains normal market status and liquidity
- Market: Restores confidence in the company’s compliance status
- Liquidity: Normal trading volumes and price discovery mechanisms can resume
Impact Justification
Revocation of trading suspension is significant for the affected company and its shareholders, allowing normal trading activity to resume